A Comparative Study of the Use of Navoban (ICS 205-930), a 5-HT3 Antagonist, versus a Standard Antiemetic Regimen of Dexamethasone and Metoclopramide in the Treatment of Cisplatin-Containing Chemotherapy
- 1 September 1993
- journal article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 6 (3) , 162-169
- https://doi.org/10.1007/bf03259737
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Compassionate Use of a 5-HT3-Receptor Antagonist, Tropisetron, in Patients Refractory to Standard Antiemetic TreatmentDrugs, 1992
- TropisetronDrugs, 1992
- FIRST RESULTS WITH ICS 205-930 (5-HT3 RECEPTOR ANTAGONIST) IN PREVENTION OF CHEMOTHERAPY-INDUCED EMESISThe Lancet, 1987
- The Management of Chemotherapy-Induced Nausea and VomitingMedical Clinics of North America, 1987
- Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonismBritish Journal of Pharmacology, 1986
- Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.Journal of Clinical Oncology, 1985
- Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and VomitingNew England Journal of Medicine, 1981